| NCT ID | NCT06928675 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Basel, Switzerland |
| Condition | Stroke |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-03-30 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-03-30 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Cell-free DNA (cfDNA) is an important pro-inflammatory and prothrombotic mediator. With this study the investigators aim to gain new insights into the role of cfDNA in stroke and to perform a combined analysis of cfDNA in the hyperacute phase of the disease using blood and thrombus analyses. The main objectives are to analyse cfDNA in different stroke etiologies, to investigate the relationship between cfDNA and important procedural factors such as secondary embolisation and reperfusion outcomes, to analyse the correlation between blood and thrombus content of cfDNA and to investigate the specific source of cfDNA in distinct stroke subtypes.
Eligibility Criteria
Inclusion Criteria: * Acute ischemic stroke due to large vessel occlusion (LVO) who require mechanical thrombectomy (detected in CT-Scan or MRI-Scan) * 18 years of age Exclusion Criteria: * Patients currently undergoing immunological therapies. * Patients with immunological diseases * Patients with systemic infections at the time of admission
Contact & Investigator
Gerrit Grosse, PD Dr. Dr.
PRINCIPAL INVESTIGATOR
University Hospital, Basel, Switzerland
Frequently Asked Questions
Who can join the NCT06928675 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Stroke. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06928675 currently recruiting?
Yes, NCT06928675 is actively recruiting participants. Contact the research team at gerrit.grosse@usb.ch for enrollment information.
Where is the NCT06928675 trial being conducted?
This trial is being conducted at Basel, Switzerland.
Who is sponsoring the NCT06928675 clinical trial?
NCT06928675 is sponsored by University Hospital, Basel, Switzerland. The principal investigator is Gerrit Grosse, PD Dr. Dr. at University Hospital, Basel, Switzerland. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.